3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
3
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Colorectal Neoplasms
93
Stomach Neoplasms
56
Rectal Neoplasms
51
Colonic Neoplasms
47
Pancreatic Neoplasms
21
Neoplasms
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
13
Adenocarcinoma
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Lymphoma, Large B-Cell, Diffuse
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
5
Biliary Tract Neoplasms
5
Neurotoxicity Syndromes
4
Esophageal Squamous Cell Carcinoma
4
Lymphoma, Extranodal NK-T-Cell
3
Gastrointestinal Neoplasms
3
Gallbladder Neoplasms
3
Peritoneal Neoplasms
2
Lymphoma
2
Liver Neoplasms
2
Hepatoblastoma
2
Gastrointestinal Diseases
2
Colorectal Adenocarcinoma
2
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
Cyclophosphamide
60
Vincristine
57
Doxorubicin
54
Rituximab
48
Prednisone
44
Etoposide
35
Radiotherapy
34
Cytarabine
26
Filgrastim
22
Methotrexate
21
Bleomycin
21
Dexamethasone
18
Peripheral Blood Stem Cell Transplantation
14
Carmustine
14
Vinblastine
13
Prednisolone
13
VAP-cyclo protocol
12
Melphalan
12
Mitoxantrone
11
Mercaptopurine
10
Leucovorin
10
Dacarbazine
9
Ifosfamide
8
Granulocyte Colony-Stimulating Factor
8
Procarbazine
7
Methylprednisolone
7
Lenalidomide
7
Gemcitabine
7
Daunorubicin
7
Cisplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma
×
Oxaliplatin
×
Clear all
NCT04384484
2026-04-28
LOTIS 5
ADC Therapeutics S.A.
Phase 3
Active not recruiting
440 enrolled
NCT04182204
2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3
Completed
270 enrolled
36 charts